3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
7
Ovarian Neoplasms
4
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Multiple Myeloma
2
Mouth Neoplasms
2
Lymphoma
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
1
Interventions
pembrolizumab
2
atezolizumab
2
Paclitaxel
2
Carboplatin
2
veliparib
1
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
entrectinib
1
cobimetinib
1
alectinib
1
Whole Genome Sequencing
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Taxes
1
Surveys and Questionnaires
1
Specimen Handling
1
Sequence Analysis, RNA
1
Radiosurgery
1
Magnetic Resonance Spectroscopy
1
HhAntag691
1
Genetic Testing
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Erlotinib Hydrochloride
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
ipatasertib
×
1 year
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts